Literature DB >> 17544654

Liver resection for colorectal liver metastasis.

R Lochan1, S A White, D M Manas.   

Abstract

At some point in the natural course of colorectal cancer up to 50% of patients will develop metastasis to the liver. Historically only 20% of these patients would have to be deemed resectable, with an intent to cure, at the time of presentation. But with recent improvements in cross-sectional imaging, chemotherapeutic agents and advances in the techniques of surgical resection the emphasis of resection has now changed to 'who is not resectable' as opposed to 'who is resectable'. There are few contraindications to liver resection on the proviso that the patient is fit enough. As a result of this paradigm shift, 5 year survival rates are approaching 60%. Historically liver resection was perceived as a formidable operation but now liver resection for CRLM is safe and specialist centres are reporting mortality rates of less than 1%. This review briefly covers the standard techniques currently employed and some of the recent innovations being developed to improve resectability.

Entities:  

Mesh:

Year:  2007        PMID: 17544654     DOI: 10.1016/j.suronc.2007.04.010

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  19 in total

1.  General principles of hepatectomy in colorectal liver metastases.

Authors:  I Maroulis; D D Karavias; D Karavias
Journal:  Tech Coloproctol       Date:  2011-10       Impact factor: 3.781

Review 2.  Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer.

Authors:  Jianmin Xu; Xinyu Qin; Jianping Wang; Suzhan Zhang; Yunshi Zhong; Li Ren; Ye Wei; Shaochong Zeng; Deseng Wan; Shu Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-28       Impact factor: 4.553

3.  Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastases.

Authors:  Yanxin Luo; Lei Wang; Chuangqi Chen; Dianke Chen; Meijin Huang; Yihua Huang; Junsheng Peng; Ping Lan; Ji Cui; Shirong Cai; Jianping Wang
Journal:  J Gastrointest Surg       Date:  2010-07-30       Impact factor: 3.452

Review 4.  Sinusoidal obstruction syndrome (hepatic veno-occlusive disease).

Authors:  Cathy Q Fan; James M Crawford
Journal:  J Clin Exp Hepatol       Date:  2014-10-30

5.  More than 7-year survival of a patient following repeat hepatectomy for total 20 colon cancer liver metastases.

Authors:  Kwang Ho Yang; Je Ho Ryu; Ki Myung Moon; Chong Woo Chu
Journal:  J Korean Surg Soc       Date:  2012-01-27

6.  The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis.

Authors:  Jason L Townson; Ian C Macdonald; Karen T Liby; Lisa Mackenzie; David W Dales; Benjamin D Hedley; Paula J Foster; Michael B Sporn; Ann F Chambers
Journal:  Clin Exp Metastasis       Date:  2011-01-15       Impact factor: 5.150

7.  SBRT planning for liver metastases: A focus on immobilization, motion management and planning imaging techniques.

Authors:  Olivier Riou; Carmen Llacer Moscardo; Pascal Fenoglietto; Emmanuel Deshayes; Raphaël Tetreau; Jessica Molinier; Alexis Lenglet; Eric Assenat; Marc Ychou; Boris Guiu; Norbert Aillères; Ludovic Bedos; David Azria
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-06

8.  Accomplishments in 2008 in the management of curable metastatic colorectal cancer.

Authors:  René Adam; Emir Hoti; Gunnar Folprecht; Al B Benson
Journal:  Gastrointest Cancer Res       Date:  2009-09

9.  Whole-liver radiotherapy for end-stage colorectal cancer patients with massive liver metastases and advanced hepatic dysfunction.

Authors:  Seung-Gu Yeo; Dae Yong Kim; Tae Hyun Kim; Sun Young Kim; Yong Sang Hong; Kyung Hae Jung
Journal:  Radiat Oncol       Date:  2010-10-26       Impact factor: 3.481

10.  Accomplishments in 2007 in the management of curable metastatic colorectal cancer.

Authors:  Amit Shah; Steven Alberts; René Adam
Journal:  Gastrointest Cancer Res       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.